Liquidia Corporation

LQDA

US53635D2027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
12.44 ^USD	-1.35%		0.00%	+3.41%

07-01	Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000E Value Index	CI
07-01	Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000 Value Index	CI

Liquidia Corporation Approves the Ratification of the Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for the Year Ending December 31, 2024

June 21, 2024 at 04:30 pm

Liquidia Corporation at its annual meeting of stockholders held on June 20, 2024, approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company?s independent registered public accounting firm for the year ending December 31, 2024.

Latest news about Liquidia Corporation

Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000E Value Index	06-30	CI
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000 Value Index	06-30	CI
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 2500 Value Index	06-30	CI
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell Small Cap Comp Value Index	06-30	CI
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 2000 Value Index	06-30	CI
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell Microcap Value Index	06-30	CI
Oppenheimer Initiates Liquidia at Perform	06-25	MT
Liquidia Corporation Approves the Ratification of the Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for the Year Ending December 31, 2024	06-21	CI
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	06-03	MT
Liquidia Shares Jump on Latest Favorable Court Ruling for Yutrepia	06-03	DJ
District Court Issues Favorable Ruling and Denies United Therapeutics? Request to Block YUTREPIA? Launch	06-03	CI
Transcript : Liquidia Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 05:01 PM	05-14
Transcript : Liquidia Corporation, Q1 2024 Earnings Call, May 14, 2024	05-14
Liquidia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	04-01	MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	04-01	DJ
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	03-20	MT
Liquidia Corporation(NasdaqCM:LQDA) added to S&P Pharmaceuticals Select Industry Index	03-17	CI
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating	03-14	MT
Transcript : Liquidia Corporation, 2023 Earnings Call, Mar 13, 2024	03-13
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell	03-13	MT
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Certain Stock Units of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	03-11	CI
Certain Warrants of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	03-11	CI
Certain Options of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	03-11	CI

Chart Liquidia Corporation

Duration

Period

More charts

Company Profile

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Liquidia Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.44 USD

Average target price

27.67 USD

Spread / Average Target

+122.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIQUIDIA CORPORATION	+3.41%	951M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.13%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.63%	244B
ROCHE HOLDING AG	+5.07%	234B
NOVARTIS AG	+16.18%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals